tbuckley/cabot-search huggingface dataset:
986P Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study
Authors: H. Chon, J. Heo, T.R.J. Evans, D.Y. Kim, H.Y. Lim, T. Macarulla Mercade, C. Gomez Martin, V. Moreno Garcia, M.H. Ryu, P. Baumann, S. Bhoi, M. Jensen, K. Tunblad, H. Wallberg, F.G. Öberg, M.E. Reig Monzon
Journal: Annals of Oncology (2024)
1111P Genomic and transcriptomic analysis of Japanese melanoma reveals candidate biomarkers for immune checkpoint inhibitor responders
Authors: T. Kimura, N. Tanaka, T. Maekawa, Y. Kiniwa, R. Okuyama, J. Asai, S. Matsushita, H. Uchi, H. Kato, K. Nagase, A. Kobayashi, A. Tanemura, T. Fujimura, H. Yano, T. Noda, K. Kiyotani, S. Mori, S. Fukushima
Journal: Annals of Oncology (2024)
934P Harnessing artificial intelligence on real-world data to predict recurrence in head and neck squamous cell carcinoma patients: The HNC-TACTIC study
Authors: H. Mehanna, S. Baliga, M.L.K. Chua, P. Parente, A. Castro Calvo, J. Rogado, V. Gonzalez, F. Aguilar, D. Culie, A. Sanabria, M. Guiz, J. Davies, M. Stoehr, S.F. Zuñiga, R. Giger, M. López, E. Castillo, L. Cabal Hierro, H.T. Study Group, M. Taberna
Journal: Annals of Oncology (2024)
461P Effectiveness of dabrafenib-trametinib and larotrectinib in adult recurrent glioblastoma patients: A real-life cohort analysis from 3 Italian centers
Authors: M. Padovan, E. Cella, A. Bosio, M. Maccari, G. Cerretti, M. Caccese, M. Corrà, P. Giordano, E. Bennicelli, G. Lombardi
Journal: Annals of Oncology (2024)
883P Oral rehabilitation after mandibular reconstruction for head and neck malignancy: A multicenter study
Authors: L.M. Roussel, R. Elaldi, E. Lévêque, M. Anquetil, A. Lasne Cardon, E. Babin, A. Bozec, V. Bastit, A. Boulay, E. Brenet, F. Clatot
Journal: Annals of Oncology (2024)
943TiP Petosemtamab compared with investigator’s choice monotherapy in previously treated patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial
Authors: R. Haddad, M. Gillison, K.J. Harrington, S-B. Kim, C. Le Tourneau, A. Rosenberg, J. Ford, Y-M. Shen, D. Yao, F. Zohren, J-P. Machiels
Journal: Annals of Oncology (2024)
946P Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study
Authors: J.S. Kim, B. Kang, C. An, Y. Kang, I. Kim, H. Kim, C. Kim, H. Chon
Journal: Annals of Oncology (2024)
466P Re-irradiation therapy for pediatric brainstem tumours: 20 years of clinical experience
Authors: O. Regentova, O. Sherbenko, R. Parhomenko, F. Antonenko, N. Zelinskaya, N. Sidibe, A. Shevtsov, P. Polushkin, M. Bliznichenko, V. Deyanova, V. Solodkiy
Journal: Annals of Oncology (2024)
487P 3D-bioprinted co-cultures of glioblastoma and mesenchymal cells indicate a role for perivascular niche cells in shaping the chemotactic tumour microenvironment
Authors: R. Zagożdżon, K. Zielniok, K. Rusinek, M. Lachota, E. Baczynska, A. Slysz, N.K. Krata, B. Foroncewicz, K. Mucha, Z. Pojda
Journal: Annals of Oncology (2024)
914P The landscape of somatic copy number alterations of head and neck squamous cell carcinoma across different anatomic sites
Authors: J.C. Redondo González, A. Olivares Hernandez, J.L. Garcia Hernandez, R. Mesia Nin, J. Rubió-Casadevall, C. Garcia Giron, L. Iglesias Docampo, A. Carral Maseda, M. Taberna Sanz, S. Vázquez Fernández, L.A. Corchete Sánchez, N. Gestoso Uzal, R. González Sarmiento, E. Fonseca Sánchez, J.J. Cruz Hernandez, E. del Barco Morillo
Journal: Annals of Oncology (2024)
900P Notch inhibitor AL101 prior to surgery in patients (pts) with Notch1 activated adenoid cystic carcinoma (ACC): Safety and efficacy in a window of opportunity study
Authors: R. Ferrarotto, D. McGrail, Y. Mitani, E. Santos, F. Johnson, M. Chen, K. Li, S-Y. Lin, S. Frank, J.J. Lee, M. Williams, B. Esmaeli, A. El-Naggar, E. Hanna
Journal: Annals of Oncology (2024)
910P Multi-omics analysis of tislelizumab plus nab-paclitaxel and cisplatin as neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: A prospective single-arm phase II trial
Authors: Z. Xie, W. Zhang, X. Chen, X. Wang, S. Liu, J. Yi, C. An, H. Lu, J. Yao, H. Zhu, T. Xie, L. Tang, X. He, Y. Shi, L. Gui
Journal: Annals of Oncology (2024)
1264P Real-world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Authors: J.V. Heymach, E. Dardenne, J. Liao, C. Guzman, S. Eathiraj, N. Zhang, M. Nilsson, Y.Y. Elamin, X. Le, E. Buck
Journal: Annals of Oncology (2024)
966P Borderline resectable hepatocellular carcinoma: Definitions, efficacy and safety results from a prospective phase Ib/II study evaluating camrelizumab plus lenvatinib combined with TACE as preoperative therapy (BRHCC)
Authors: M. Liao, Y. Yang, H. Jiang, J. Huang, C. Liu, Y. Yang, K. Xie, X. Luo, J. Zhou, X. Wang, H. Wu, Y. Zeng, Q. Li
Journal: Annals of Oncology (2024)
1250P Impact of systemic treatment on cardiac events following chemoradiotherapy in stage III lung cancer patients
Authors: J. Sanz Beltran, S. Martinez Recio, E. Otero, A. Barba Joaquín, I.G. Sullivan, A.M. Soto, M.A. Molina Pérez, N. Farré, M. Majem
Journal: Annals of Oncology (2024)
1153P Preclinical characterization of MC339: A novel radiotherapeutic agent for DLL3 expressing cancers
Authors: A. Savinainen, L. Wu, T. Bruton, A. Chonkar, J. Cupido, J. Dearling, C. Huang, K. Lee, Z. Ma, H. Mok, K. Nabi, A. Salih, A. Sutton, L. Tavera, M. Wan, Z. Wang, X. Xu, J. Xu, A. Zidell, A. Ricardo
Journal: Annals of Oncology (2024)
CN93 Quality of life scale-based machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer
Authors: J. Shen, J. Ma, S. Chen, Q. Li, S-H. Jin, C. Zhang, None H. wang, X. Chen, F. Tan, X. Tian, H. Zhang, G. Pan, U. Gaipl, H. Ma, J-G. Zhou
Journal: Annals of Oncology (2024)
1243MO A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914
Authors: S. Omori, H. Kenmotsu, T. Takahashi, S. Nomura, H. Harada, S. Ishikura, M. Ando, H. Izumi, Y. Shinno, M. Oki, T. Masuda, T. Yokoyama, Y. Hosomi, T. Shimokawa, S. Murakami, T. Kurosaki, H. Yoshioka, N. Mitome, H. Fukuda, Y. Ohe
Journal: Annals of Oncology (2024)
876P Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)
Authors: X. Chen, M. Hu, T. Jin, K. Teng, Y. Han, Y. Zhou, K. Yang, Z. Zhang, J. Wang, Y. Cheng, W. Li, Z.M. Wang, B. Li, Y. Xia
Journal: Annals of Oncology (2024)
1223P Sex specific efficacy and safety outcomes in operable stage III non-small cell lung cancer (NSCLC): Pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
Authors: L. Frehner, S. Schaer, S. Hayoz, M. Guckenberger, T. Finazzi, M.T. Mark, A. Addeo, L.A. Mauti, D.C. Betticher, R. Stupp, A. Curioni-Fontecedro, S. Peters, M. Frueh, S.I. Rothschild, M. Pless, D. König, I. Schmitt-Opitz, H-B. Ris, B.C. Özdemir, S. Schmid
Journal: Annals of Oncology (2024)
895P Cost effectiveness of stereotactic ablative radiotherapy (SABR) alone in comparison with systemic treatment and SABR in oligometastatic head and neck cancer in the GORTEC 2014-04 OMET randomized phase II study
Authors: J. Thariat, A. Falcoz, L. Nadin, J. Bourhis, X. Sun, V. Nerich
Journal: Annals of Oncology (2024)
1127P Subgroup analysis of FOCUS phase III trial efficacy results
Authors: M. Wheater, M. Orloff, P.F. Ferrucci, J. Choi, D. Eschelman, E. Glazer, A. Ejaz, E. Richtig, S. Ochsenreither, S.A. Reddy, M. Lowe, G. Beasley, A. Gesierich, M. Gschnell, R. Dummer, A.M. Arance, S. Fenwick, J. John, C.H.H. Ottensmeier, J.S. Zager
Journal: Annals of Oncology (2024)
1249P Health-related quality of life (HRQoL) at diagnosis for unresectable stage III NSCLC: Results from the French nationwide prospective study OBSTINATE (GFPC 06-2019)
Authors: C. Ricordel, A. Anota, I. Monnet, S. Martinez, Y. Simmoneau, L. Falchero, F. Guisier, G. De Chabot, S. Abdiche, G. Quere, S. Hominal, A. Demaegdt, J. Le Treut, S. Bayle, J. Pinsolle, T. Chatellier, L. Kaluzinski, S. Vieillot, C. Chouaid, L. Greillier
Journal: Annals of Oncology (2024)
894P AXEL: AXitinib-avELumab combination in recurrent or metastatic (RM) nasopharyngeal cancer (NPC)
Authors: E.P. Hui, B.B.Y. Ma, F. Mo, L. Li, K.H. Wong, W.W. Lai, Q.H. AI, A.D. King, C.H. Wong, C.M. Chan, W.K.J. Lam, A.K. Chan, A.T. Chan
Journal: Annals of Oncology (2024)
1070TiP A phase Ia/Ib dose-escalation/expansion study of NPX887 in subjects with solid tumor malignancies known to express HHLA2/B7-H7
Authors: H. Cheng, I.I. Rodriguez Rivera, D.F. McDermott, A.I. Spira, Y. Ged, J. Liu, Y. Ji, M. Rausch, Y. Hashambhoy-Ramsay, K. Kis-Toth, L. Gandhi, A. Naing
Journal: Annals of Oncology (2024)
919P Predictive multi-omic signature in locally advanced laryngeal/hypopharyngeal (LH) squamous cell carcinoma (SCC) treated with induction chemotherapy (IC)
Authors: P. Bossi, D. Mattavelli, S. Chiocca, C. Gurizzan, M. Compagnoni, A. Dietz, E. Hovig, M. Kalogerini, K. Khelik, L. Lorini, R. Mesia Nin, M. Plana Serrahima, M. Ravanelli, P. Rondi, D. Smussi, G. Wichmann, Z. Yinxhiu, S. Calza
Journal: Annals of Oncology (2024)
843P Challenges and insights in treating Langerhans cell histiocytosis: Persistent mutations and novel therapeutic approaches
Authors: M. Nashvi, Z. Hélias-Rodzewicz, J. Rengassamy, C. Bigenwald, C. Quivoron, J-F. Emile, N. Urvoy, J. Haroche, S. Héritier
Journal: Annals of Oncology (2024)
963P Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab + rivoceranib (cam+rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310
Authors: A. Moon, N. Raphael, S.L. Chan, A.O. Kaseb, S.H. Jang, X. Meng, A-L. Cheng, S. Qin, A. Vogel
Journal: Annals of Oncology (2024)
871P Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study
Authors: L. Iglesias Docampo, N. Baste Rotllan, M. Oliva Bernal, A. Carral Maseda, P. Pérez Segura, A. Medina Colmenero, B. Cirauqui Cirauqui, V. Arrazubi Arrula, J. Martinez Trufero, V. Gutierrez Calderon, A. Garcia Castano, J. Rubió-Casadevall, L. Basterretxea, R. Alvarez Cabellos, E. del Barco Morillo, G. Bruixola, M.J. Flor, J.D. Assaf Pastrana, J. Caballero Daroqui, R. Mesia Nin
Journal: Annals of Oncology (2024)
442O A phase I clinical trial of intrathecal injection of allogeneic CAR-γδT cells targeting B7H3 for the treatment of patients with recurrent glioblastoma
Authors: X. Li, W. Ma, Y. Gu, Y. Sui, X. Zhang, C. Wang, W. Gan, J. Chen, L. Wang, Y. Zhang, Y. Zhang, Y. Huang
Journal: Annals of Oncology (2024)
867MO Epigenetic therapy modulates the tumor microenvironment to sensitize anti-PD-1 refractory head and neck cancers to immunotherapy
Authors: S. Pai, T. Qin, A. Mattox, J. Campbell, J.C. Park, K-Y. Shin, P. Sadow, W. Faquin, R. Haddad, M. Pittet, C. Garris, T. Mempel, A. Oneill, M. Sartor
Journal: Annals of Oncology (2024)
CN97 Impact of a proactive telephone intervention led by the advanced practice nurse aimed at symptom control and toxicity detection on the quality of life of outpatients with lung cancer undergoing treatment
Authors: I. Brao Perez, M. Arellano, F. Torrent, S. Padrones, E. Nadal, R. Palmero Sanchez, M. Jové Casulleras, J. Brenes Castro, M.A. Mosteiro Lamas, J. Saldaña Cañada, R.A. Portolés
Journal: Annals of Oncology (2024)
1098P Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial
Authors: R.J. Sullivan, M. Lu, S. Koppolu, J.S. Weber, M.S. Carlino, M.A. Khattak, G. Ansstas, M.H. Taylor, M. Mckean, G.V. Long, M.B. Faries, J.J. Luke, V. Sehgal, A. Rao, H. Mao, J. Guo, M. Brown, R. Meehan, I. Feldman, L. Srinivasan
Journal: Annals of Oncology (2024)
908P Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005
Authors: S. Seo, B. Calderon, H-H. Chou, C-H. Hsu, P. Salman, F. Ghiringhelli, O. Ozyilkan, C.I. Rojas, M.A.N. Sendur, C. Le Tourneau, C.J. Yen, R. Shapira-Frommer, S.Y. Rha, Y. Zhang, C. Chen, C.E. Pena, T. Keenan, Y. Chen, E. Dettman, A.G. Robinson
Journal: Annals of Oncology (2024)
922P Genomic instability as a biomarker for advanced cancer of the head and neck
Authors: F.G. Dall'Olio, W.S. Zrafi, D. Al Burshaid, J. Bassil, V.V. Pop, D. Vasseur, L. lacroix, P. Kannouche, K. Benihoud, I. Breuskin, C. Even
Journal: Annals of Oncology (2024)
878P Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+ oropharyngeal cancer that progressed with prior anti-PD-1 therapy
Authors: A. Kong, C. Even, B. Aguilera, M. Klein Hesselink, S. Visscher, C.H. Chung, J.C. Park, D.R. Adkins, S. Salas, K.J. Harrington, J. Fayette, S. Rottey, A. Algazi, M.G. Fury, C.J.M. Melief, L.W. Hooftman
Journal: Annals of Oncology (2024)
861P Neo-TIME trial: Neoadjuvant tislelizumab combined with albumin-paclitaxel, cisplatin, and fluorouracil(APF) in patients with locally advanced oral squamous cell carcinoma (LA-OSCC)
Authors: W. Zhao, Y. Ni, W. Zhu, L. Ruan, Y. Gao, X. Zhu, J. Zhou, W. Fang, L. Liu
Journal: Annals of Oncology (2024)
423P Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada
Authors: P. Thomas, B. Carter, C. Earle, S. Sharriff, J. Raphael, A. Mahar, S. Knowles, None M. brackstone, M. Lock, A. Eisen, P. Blanchette
Journal: Annals of Oncology (2024)
1094P NeoRisk: Neoadjuvant immunotherapy (NeoIT) recurrence risk assessment tool
Authors: I. Pires da Silva, P. Grover, N.A. Adegoke, R. Rawson, N. Maher, A. Colebatch, J.W. Conway, M.S. Carlino, S.N. Lo, A.M. Menzies, R.A. Scolyer, G.V. Long
Journal: Annals of Oncology (2024)
420P An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples
Authors: S. Statt, J.R. Thibert, M. Church, J. Myers, H. Dale, B. Caughron, K. Kelnar, B. Haynes
Journal: Annals of Oncology (2024)
848MO Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)
Authors: W.Q. Chong, J.L. Low, K. Sooi, R.A. Soo, C. le, H.L. Teo, J. Samol, G. Goh, L.R. Kong, R. DasGupta, S. Chia, R. Wong, A. Gopinathan, J.K. Tay, D. Eu, R. Tsang, K-S. Loh, B.C. Tai, Y.C. Lim, B-C. Goh
Journal: Annals of Oncology (2024)
416P Prognostic impact of liquid biopsy (LB) biomarkers at relapse on second-line (2L) treatment (Tx) after progression to endocrine therapy (ET) in metastatic breast cancer (mBC): Ancillary analysis of the MAGNETIC.1 study
Authors: A. Dri, L. Foffano, E. Molteni, A. Franzoni, L. Lay, L. Cucciniello, L. Da Ros, S. Buriolla, S. Bolzonello, C. Noto, S. Russo, S. Spazzapan, E. Nascimbeni, B. Pastò, M. Bonotto, A.M.M. Minisini, G. Damante, B. Belletti, L. Gerratana, F. Puglisi
Journal: Annals of Oncology (2024)
1042P Rapid, single-step monitoring of circulating monoclonal antibodies using an aptamer-based electrochemical sensing platform
Authors: R. Ergasti, A. Porchetta, C. Nero, C. Marchetti, E. Palluzzi, O. Martelli, V. Accinno, I. Marino, M. Buttarelli, F. Alcaro, A. Garcia Chamorro, A. Idili, G. Ferrandina, G. Scambia
Journal: Annals of Oncology (2024)
1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)
Authors: A. Elkrief, S. Duttagupta, R. Jamal, N. Marcoux, A. Desilets, M. Messaoudene, C. Mihalcioiu, S. Durand, M. Tehfe, N. Blais, S. Owen, J. Raphael, J.G. Lenehan, S.N. Parvathy, L. Derosa, L. Zitvogel, G. Kroemer, M. Silverman, S. Maleki Vareki, B. Routy
Journal: Annals of Oncology (2024)
1018P Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer
Authors: O. Saavedra Santa Gadea, A. Oberoi, J.S. Lopez, A. Cervantes, M. Ponz-Sarvise, H.R. Kim, A.B. El-Khoueiry, B. Shim, J.W. Kim, V. Boni, I. Lugowska, C. Szczylik, W. Rogowski, S. Mandziuk, R. Ramlau, U. Gaertner, S. Lutkewitz, D. Schütz, M. Emig, D. Morales-Espinosa
Journal: Annals of Oncology (2024)
358P Everolimus or ribociclib in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and circulating tumor cells: Results from DETECT IVa
Authors: T.N. Fehm, F. Schochter, B. Rack, P. Wimberger, M. Banys- Paluchowski, H. Neubauer, L. Wiesmueller, F. Meier-Stiegen, P.A. Fasching, J-U. Blohmer, A.D. Hartkopf, S. Heublein, J. Huober, S. Riethdorf, K. Pantel, A. Schneeweiss, T.W.P. Friedl, V. Mueller, W. Janni
Journal: Annals of Oncology (2024)
554P Novel clinical decision support (CDS) system optimizing adjuvant chemotherapy (ACT) for colorectal cancer (CRC) by integrating deep learning and circulating tumor DNA (ctDNA) molecular residual disease (MRD): GALAXY histotyping
Authors: Y. Nakamura, W. Kildal, T. Misumi, M. Pradhan, J. Watanabe, O-J. Skrede, D. Kotani, S.D. Raedt, H. Bando, J. Kalsnes, H. Taniguchi, K. Liestøl, I. Takemasa, T.S. Hveem, T. Kato, M. Novelli, E. Oki, D.J. Kerr, T. Yoshino, A. Kleppe
Journal: Annals of Oncology (2024)
413P Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors
Authors: T.A. Yap, F. Liu, H. Zhang, W. Roh, A. Giordano, E.P. Hamilton, M.L. Delioukina, M. Lira, J. Park, C. Basu, M.R. Sharma
Journal: Annals of Oncology (2024)
870P POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
Authors: M.D. Forster, J. Mason, R. Moleron, J.J. Sacco, M. Beasley, M. Reis Ferreira, D. Srinivasan, K. Yip, G. Stewart, K. Chiu, A. Ward, R. Metcalf, T. Adedoyin, R. Begum, M. Chiwewe, K. Poole, V. Spanswick, Y. Pathak, N. Counsell, M.K. Rashid
Journal: Annals of Oncology (2024)
557P Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Authors: B. Wang, J. Liu, B. Deng, Q. Li, Q. Xiao, W. Liu, Y. Chen, H. Liu, Y. Li, Q. Yuan, C. Wang, H. Jia, B. li, Y. Zhang, Y. Ding, D. Xu, R. Liu, J. Fang, J. Wu
Journal: Annals of Oncology (2024)
381P Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience
Authors: K.H. Natsuhara, M. Vella, S.C. Behr, L. Quintal, J. Chien, M.E. Melisko, M. Majure, G.C. Buckle, A.H. Ko, H.S. Rugo
Journal: Annals of Oncology (2024)
939TiP Phase II multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of HB-200 in patients with detectable TTMV-HPV DNA after definitive treatment for HPV16 + HNSCC
Authors: A.L. Ho, N. Riaz, D. Pfister, R. Wong, N. Lee, E.J. Sherman, S. Haque, I. Ostrovnaya, W. Wong
Journal: Annals of Oncology (2024)
1054P CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment
Authors: M. Provencio Pulla, M. Cobo Dols, D. Rodriguez Abreu, E. Carcereny, R. López Castro, M.R. García Campelo, R. Bernabe Caro, J. Bosch-Barrera, B. Massuti Sureda, A. Sanchez Hernandez, A.L.O. Ortega Granados, M. Guirado, E. del Barco Morillo, C.J. Camps, J. Casal Rubio, M. Dómine Gómez, M.A. Sala Gonzalez, K. Medina Sanchez, J.L. Gonzalez-Larriba, G. Suay Montagud
Journal: Annals of Oncology (2024)
507O Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer: Final results of the phase II randomized multicenter LEANOX trial
Authors: E. Assenat, M. Ben Abdelghani, S. Gourgou, H. Perrier, F. Khemissa Akouz, R. Desgrippes, M.P. Galais, C. Janiszewski, Y. Rinaldi, C. Lepage, R. Tetreau, P. Senesse
Journal: Annals of Oncology (2024)
368P Tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR+/HER2- advanced breast cancer after CDK4/6 inhibitors: Preliminary findings of a multi-center, phase II study
Authors: Q. Zheng, H. Zhou, H-L. Wu, Y. Cai, L-M. Chen, J. Huang, R. Hong, W. Xia, K. Jiang, F. Xu, S. Wang
Journal: Annals of Oncology (2024)
361P PALVEN: A phase Ib study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
Authors: C. Muttiah, F. Martin, M. Christie, S-J. Dawson, J. Desai, L. Lal, K. Moodie, A. Murugasu, P. Phan, M. Rosenthal, A. Travers, J. Visvader, J.R. Whittle, G. Lindeman
Journal: Annals of Oncology (2024)
CN65 Quality of endometrial cancer care from the patients’ perspective: A cross-sectional study
Authors: C. Olsson, M. Larsson, E. Holmberg, K. Stålberg, C. Sköld, A. Floter-Radestad, M. Bjurberg, P. Dahm-Kähler, K. Hellman, P. Kjolhede, B. Wilde Larsson, E.H. Avall-Lundqvist, C. Borgfeldt
Journal: Annals of Oncology (2024)
928P Radiomic analysis based on machine learning of multi-MR sequences to assess early treatment response in locally advanced nasopharyngeal carcinoma
Authors: L. Qiu, Y. Fei, W. Xu, J. Yuan, M. Wu, Y. Zhu, K. Shi, Y. Li, J. Luo, D. Cao, S. Zhou
Journal: Annals of Oncology (2024)
555P Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Authors: T. HARIMA, R. Yamashita, Y. Nakamura, S. Sakai, R. Nomura, M. Saori, D. Kotani, H. Taniguchi, J. Watanabe, I. Takemasa, T. Kato, E. Oki, T. Yoshizumi, T. Yoshino
Journal: Annals of Oncology (2024)
1086P Intratumoral (IT) administration of autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with the immunologic adjuvant AS01B plus ipilimumab (IPI) and IV nivolumab (NIVO) in patients with refractory advanced melanoma: A phase Ib clinical trial
Authors: M. Vounckx, I. Dirven, J.I. Kessels, L. Stevens, X. Geeraerts, A. Boisson, I. Van Riet, R. Forsyth, K. Willard-Gallo, S. Tuyaerts, B. Neyns
Journal: Annals of Oncology (2024)
1067P Steroid and antibiotic treatment are associated with diverse immunotherapy efficacy: A pooled analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC trials of the German AIO study group
Authors: I. Wiest, R. Keller, M. Marin-Galiano, F. Zengerling, J. Tintelnot, M-O.J. Grimm, K. Leucht, F. Bozorgmehr, P. Christopoulos, S. Rieken, J. Meran, A. Stein, M. Binder, N. Härtel, K. Klinghammer, V. Gruenwald, M. Pogorzelski, M. Ebert
Journal: Annals of Oncology (2024)
330P Randomized phase II study of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients
Authors: S.A. Elsamany Mohammed, O. Elemam, A.M.I. Al-Gahmi, F. Hassanin, T. Hamid, H.A. Alghanmi
Journal: Annals of Oncology (2024)
1008P Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Authors: L. Gil Bazo, J. Yi, K. Ma, A. Chaudhry, D. Vicente Baz, O. Mirallas, Y. Guo, M. Tea, X. Shen, H.C. Gong, X. Pu, V. Boni
Journal: Annals of Oncology (2024)
1055P Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancers
Authors: A. Avanzo, F. Salomone, S. D'Ambrosio, F. Vitale, A. Viggiano, L. Liguori, F. Napolitano, A. Santaniello, L. Formisano, R. Bianco, A. Servetto
Journal: Annals of Oncology (2024)